Science Corporation hits $3.5B valuation after $400M Series D round
Science Corporation, the brain-tech startup founded by former Neuralink president Max Hodak, raised $400 million in a Series D round backed by Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. A person familiar with the deal told TechCrunch the round values the company at $3.5 billion. Hodak also announced at TechCrunch Disrupt that the company's PRIMA vision-restoring implant is now being trialled for Stargardt's disease in addition to macular degeneration.
GoKawiil's interpretation of the reporting above, not reported fact.
The funding could help Science pursue FDA approval for PRIMA in the US through the Humanitarian Device Exemption pathway, which applies to rare conditions, potentially opening a path to American patients after European approval. The capital also supports the company's longer-term goal of building a bio-hybrid brain sensor combining neurons and silicon, which Yale neurosurgery professor Murat Günel suggests could eventually help treat Parkinson's disease and other brain conditions, though this work remains in early trial design.
- Science Corporation raised a $400 million Series D at a $3.5 billion valuation
- PRIMA, its vision-restoring implant, is now being trialled for Stargardt's disease alongside macular degeneration
- The company is pursuing FDA approval via the Humanitarian Device Exemption and developing a bio-hybrid brain sensor
Source: techcrunch.com — Tim Fernholz, 2026-11-17
Published there as: “Science Corporation’s brain tech is worth $3.5 billion after new funding”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.